Morten Frier Gjerstorff

List of Publications by Year
in descending order

51	1,732	304368	288905
papers	citations	22 h-index	40 g-index

52	52	52	2777
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	0.8	265
2	Photodynamic therapy for cancer: Role of natural products. Photodiagnosis and Photodynamic Therapy, 2019, 26, 395-404.	1.3	128
3	MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radical Biology and Medicine, 2019, 139, 1-15.	1.3	128
4	miRâ€142â€3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bachâ€1 expression. Journal of Cellular Physiology, 2019, 234, 9816-9825.	2.0	100
5	HMGA2 as a Critical Regulator in Cancer Development. Genes, 2021, 12, 269.	1.0	91
6	Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene, 2015, 34, 1919-1927.	2.6	69
7	MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Human Reproduction, 2007, 22, 953-960.	0.4	61
8	An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. Tissue Antigens, 2008, 71, 187-192.	1.0	57
9	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	3.2	56
10	Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. British Journal of Cancer, 2006, 94, 1864-1873.	2.9	54
11	Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Human Reproduction, 2008, 23, 2194-2201.	0.4	52
12	miRâ€330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer. Journal of Cellular Physiology, 2020, 235, 920-931.	2.0	51
13	miRâ€142â€3p is a tumor suppressor that inhibits estrogen receptor expression in ERâ€positive breast cancer. Journal of Cellular Physiology, 2019, 234, 16043-16053.	2.0	41
14	Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. International Journal of Molecular Sciences, 2016, 17, 890.	1.8	37
15	Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular Oncology, 2015, 9, 437-449.	2.1	33
16	HMGA2 and Bachâ€1 cooperate to promote breast cancer cell malignancy. Journal of Cellular Physiology, 2019, 234, 17714-17726.	2.0	33
17	Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer, 2013, 13, 466.	1.1	32
18	MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sciences, 2021, 276, 119431.	2.0	32

#	Article	IF	Citations
19	Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opinion on Therapeutic Targets, 2020, 24, 255-265.	1.5	30
20	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nature Communications, 2018, 9, 785.	5.8	29
21	The genes encoding bovine SP-A, SP-D, MBL-A, conglutinin, CL-43 and CL-46 form a distinct collectin locus onBos tauruschromosome 28 (BTA28) at position q.1.8-1.9. Animal Genetics, 2004, 35, 333-337.	0.6	28
22	Epigenetic Modulation of Cancer-Germline Antigen Gene Expression in Tumorigenic Human Mesenchymal Stem Cells. American Journal of Pathology, 2009, 175, 314-323.	1.9	24
23	An enzyme-linked immunosorbent assay (ELISA) for quantification of mouse surfactant protein D (SP-D). Journal of Immunological Methods, 2008, 330, 75-85.	0.6	22
24	Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions. Molecular Cancer Research, 2018, 16, 417-427.	1.5	22
25	Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer, 2011, 14, 219-225.	2.7	21
26	SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic Acids Research, 2014, 42, 11433-11446.	6.5	21
27	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. Frontiers in Immunology, 2020, 11, 1568.	2.2	20
28	Cancerâ€“germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment. Expert Opinion on Biological Therapy, 2010, 10, 1061-1075.	1.4	19
29	Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins. Nucleic Acids Research, 2019, 47, 6668-6684.	6.5	18
30	GAGE Cancer-Germline Antigens Are Recruited to the Nuclear Envelope by Germ Cell-Less (GCL). PLoS ONE, 2012, 7, e45819.	1.1	14
31	Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. International Journal of Oncology, 2006, 28, 1327-35.	1.4	14
32	The role of GAGE cancer/testis antigen in metastasis: the jury is still out. BMC Cancer, 2016, 16, 7.	1.1	12
33	Identification of miRNAs correlating with stage and progression of colorectal cancer. Colorectal Cancer, 2019, 8, CRC06.	0.8	11
34	Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer. PLoS ONE, 2015, 10, e0134967.	1.1	11
35	HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer. Cancers, 2021, 13, 5197.	1.7	11
36	Limited <scp>SP17</scp> expression within tumors diminishes itsÂtherapeutic potential. Tissue Antigens, 2012, 80, 523-527.	1.0	10

#	Article	IF	Citations
37	Genomic and molecular characterization of bovine surfactant protein D (SP-D)1. Molecular Immunology, 2004, 41, 369-376.	1.0	9
38	Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. International Journal of Oncology, 2006, 28, 1327.	1.4	9
39	Interaction between Polycomb and SSX Proteins in Pericentromeric Heterochromatin Function and Its Implication in Cancer. Cells, 2020, 9, 226.	1.8	7
40	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	2.3	7
41	The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors. Frontiers in Oncology, 2020, 10, 584024.	1.3	7
42	Human DREF/ZBED1 is a nuclear protein widely expressed in multiple cell types derived from all three primary germ layers. PLoS ONE, 2018, 13, e0205461.	1.1	6
43	Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology, 2021, 15, 3299-3316.	2.1	5
44	Expression, purification and characterization of the cancer-germline antigen GAGE12I: A candidate for cancer immunotherapy. Protein Expression and Purification, 2010, 73, 217-222.	0.6	4
45	A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell Death and Disease, 2019, 10, 841.	2.7	4
46	Novel Insights Into Epigenetic Reprogramming and Destabilization of Pericentromeric Heterochromatin in Cancer. Frontiers in Oncology, 2020, 10, 594163.	1.3	4
47	Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. Cancer Immunology, Immunotherapy, 2020, 69, 2169-2178.	2.0	4
48	Assignment of the surfactant protein A gene (SFTPA) to bovine chromosome 28q1.8â†'q1.9 by radiation hybrid mapping. Cytogenetic and Genome Research, 2004, 106, 142C-142C.	0.6	2
49	ZBED1 Regulates Genes Important for Multiple Biological Processes of the Placenta. Genes, 2022, 13, 133.	1.0	2
50	SSX2 promotes the formation of a novel type of intranuclear lamin bodies. International Journal of Biochemistry and Cell Biology, 2022, 142, 106121.	1.2	1
51	Gene expression profiling for identification of FYN in tamoxifen resistance and as predictor of early recurrence in patients treated with endocrine therapy.. Journal of Clinical Oncology, 2014, 32, 580-580.	0.8	0